Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8
What Makes Trevi Therapeutics (TRVI) a New Buy Stock
Express News | Trevi Therapeutics Announced Business Updates Ahead Of Its Participation In The 14th Annual Lifesci Partners Corporate Access Event Taking Place In San Francisco, Ca, From January 13-15, 2025
B.Riley Financial Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $11
Trevi Therapeutics Has Priced An Underwritten Offering Of 12.5M Shares At $4.00 Per Share, For Total Proceeds Of $50M
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD), Editas Medicine (EDIT) and Trevi Therapeutics (TRVI)
s
